## Michelle Whirl-Carrillo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8337095/publications.pdf

Version: 2024-02-01

54 papers 7,741 citations

35 h-index 54 g-index

58 all docs 58 docs citations

58 times ranked 9674 citing authors

#	Article	IF	CITATIONS
1	Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on ⟨i⟩MTâ€RNR1⟨ i⟩ Genotype. Clinical Pharmacology and Therapeutics, 2022, 111, 366-372.	2.3	50
2	An Investigation of the Knowledge Overlap between Pharmacogenomics and Disease Genetics. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2022, 27, 385-396.	0.7	1
3	PharmVar GeneFocus: <i>CYP3A5</i> . Clinical Pharmacology and Therapeutics, 2022, 112, 1159-1171.	2.3	14
4	Scientific evidence and sourcesÂofÂknowledge for pharmacogenomics. , 2022, , 19-51.		O
5	PharmGKB summary: acyclovir/ganciclovir pathway. Pharmacogenetics and Genomics, 2022, 32, 201-208.	0.7	2
6	PharmVar GeneFocus: <i>CYP2C19</i> . Clinical Pharmacology and Therapeutics, 2021, 109, 352-366.	2.3	72
7	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLAâ€B</i> Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	2.3	102
8	PharmGKB Tutorial for Pharmacogenomics of Drugs Potentially Used in the Context of COVIDâ $\in$ 19. Clinical Pharmacology and Therapeutics, 2021, 109, 116-122.	2.3	6
9	Pharmacogenetics at Scale: An Analysis of the UK Biobank. Clinical Pharmacology and Therapeutics, 2021, 109, 1528-1537.	2.3	78
10	PharmVar GeneFocus: <i>CYP2B6</i> . Clinical Pharmacology and Therapeutics, 2021, 110, 82-97.	2.3	108
11	Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clinical Pharmacology and Therapeutics, 2021, 110, 542-545.	2.3	62
12	An Evidenceâ€Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clinical Pharmacology and Therapeutics, 2021, 110, 563-572.	2.3	308
13	PharmVar GeneFocus: <i>CYP2C9</i> . Clinical Pharmacology and Therapeutics, 2021, 110, 662-676.	2.3	34
14	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clinical Pharmacology and Therapeutics, 2021, 110, 559-562.	2.3	6
15	PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge. Current Protocols, 2021, 1, e226.	1.3	33
16	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2021, 23, 1047-1064.	1.2	73
17	The Clinical Pharmacogenetics Implementation Consortium: 10ÂYears Later. Clinical Pharmacology and Therapeutics, 2020, 107, 171-175.	2.3	207
18	Pharmacogenomics Clinical Annotation Tool (Pharm <scp>CAT</scp> ). Clinical Pharmacology and Therapeutics, 2020, 107, 203-210.	2.3	65

#	Article	IF	CITATIONS
19	Standardizing <i><scp>CYP</scp>2D6</i> Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	1.5	353
20	PharmVar GeneFocus: <i>CYP2D6</i> . Clinical Pharmacology and Therapeutics, 2020, 107, 154-170.	2.3	156
21	PharmVar and the Landscape of Pharmacogenetic Resources. Clinical Pharmacology and Therapeutics, 2020, 107, 43-46.	2.3	50
22	Variant Interpretation in Current Pharmacogenetic Testing. Journal of Personalized Medicine, 2020, 10, 204.	1.1	5
23	Recommendations for Clinical Warfarin Genotyping Allele Selection. Journal of Molecular Diagnostics, 2020, 22, 847-859.	1.2	39
24	Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacological Research, 2020, 158, 104838.	3.1	2
25	Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Computational Biology, 2020, 16, e1008399.	1.5	32
26	PGxMine: Text mining for curation of PharmGKB. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2020, 25, 611-622.	0.7	9
27	Recommendations for Clinical CYP2C9 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2019, 21, 746-755.	1.2	84
28	Bioinformatics: Accumulating and implementing pharmacogenomics information. Drug Metabolism and Pharmacokinetics, 2019, 34, S6.	1.1	0
29	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenzâ€Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 726-733.	2.3	125
30	Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?. Clinical Pharmacology and Therapeutics, 2019, 106, 284-286.	2.3	27
31	The Evolution of PharmVar. Clinical Pharmacology and Therapeutics, 2019, 105, 29-32.	2.3	106
32	Pharmacogene Variation Consortium Gene Introduction: <i><scp>NUDT15</scp></i> . Clinical Pharmacology and Therapeutics, 2019, 105, 1091-1094.	2.3	45
33	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <i><scp>TPMT</scp></i> and <i><scp>NUDT</scp>15</i> Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	2.3	428
34	Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. Clinical Pharmacology and Therapeutics, 2019, 105, 1256-1262.	2.3	90
35	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2018, 10, e1417.	6.6	205
36	Pharmacogenomics and big genomic data: from lab to clinic and back again. Human Molecular Genetics, 2018, 27, R72-R78.	1.4	28

#	Article	IF	Citations
37	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777.	2.3	244
38	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 574-581.	2.3	211
39	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 ( <i>CYP</i> ) Allele Nomenclature Database. Clinical Pharmacology and Therapeutics, 2018, 103, 399-401.	2.3	335
40	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19, 847-860.	0.6	53
41	Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine, 2017, 19, 69-76.	1.1	365
42	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 2017, 19, 215-223.	1.1	410
43	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. American Journal of Health-System Pharmacy, 2016, 73, 1977-1985.	0.5	79
44	Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. PLoS Genetics, 2015, 11, e1005496.	1.5	23
45	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	0.7	341
46	Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1035.	3.8	398
47	In silico comparative characterization of pharmacogenomic missense variants. BMC Genomics, 2014, 15, S4.	1.2	11
48	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210.	2.3	164
49	Using ODIN for a PharmGKB revalidation experiment. Database: the Journal of Biological Databases and Curation, 2012, 2012, bas021-bas021.	1.4	18
50	Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. Cell, 2012, 148, 1293-1307.	13.5	1,134
51	From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in Medicine, 2011, 5, 795-806.	0.6	145
52	Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence. PLoS Genetics, 2011, 7, e1002280.	1.5	137
53	The BioPAX community standard for pathway data sharing. Nature Biotechnology, 2010, 28, 935-942.	9.4	613
54	Mining biochemical information: Lessons taught by the ribosome. Rna, 2002, 8, 279-289.	1.6	25